{"issuance_frequency":"","notes_translated":{"fr":"La présente ligne directrice vise à aider les promoteurs dans la collecte et l'analyse des données qu'ils doivent soumettre sur les stéroïdes nasaux utilisés dans le traitement de la rhinite allergique, pour attester que ces produits pharmaceutiques répondent aux exigences d'innocuité et d'efficacité énoncées au titre 8 de la partie C du Règlement sur les aliments et drogues.","en":"This guidance is intended to assist sponsors in the collection and analysis of data for Steroid Nasal products for use in the treatment of allergic rhinitis, in order to meet the safety and effectiveness requirements under Part C, Division 8 of the Food and Drug Regulations. "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"56795185-65af-4c0e-b7d8-6c95442d4d1c","metadata_created":"2021-06-01T19:31:50.336166","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-01T19:31:50.336172","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-01","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["document d'orientation","exigences en matière de données","sécurité et efficacité","produits nasaux stéroïdiens","traitement de la rhinite allergique","Règlement sur les aliments et drogues"],"en":["guidance document","data requirements","safety and effectiveness","steroid nasal products","treatment of allergic rhinitis","Food and Drug Regulations"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Publication de la version finale de la ligne directrice Exigences relatives à l'innocuité et l'efficacité des stéroïdes pour pulvérisation nasale de commercialisation subséquente utilisés dans le traitement de la rhinite allergique à l'intention de l'industrie","en":"Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"56795185-65af-4c0e-b7d8-6c95442d4d1c","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9e7849ac-422d-4c23-9ce8-e9087b016e3e","related_relationship":"","name_translated":{"fr":"Publication de la version finale de la ligne directrice Exigences relatives à l'innocuité et l'efficacité des stéroïdes pour pulvérisation nasale de commercialisation subséquente utilisés dans le traitement de la rhinite allergique à l'intention de l'industrie","en":"Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry","language":["en"],"created":"2021-06-01T19:31:50.408443","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/release-final-guidance-document-data-requirements-safety-effectiveness-subsequent-market-entry-steroid-nasal-products-use-treatment-allergic-rhinitis.html","last_modified":null,"position":0,"revision_id":"98ea089c-99f2-4e64-aa38-f308351d49d2","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"56795185-65af-4c0e-b7d8-6c95442d4d1c","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"27b7e79d-17b9-431b-9530-da23df2f00ec","related_relationship":"","name_translated":{"fr":"Publication de la version finale de la ligne directrice Exigences relatives à l'innocuité et l'efficacité des stéroïdes pour pulvérisation nasale de commercialisation subséquente utilisés dans le traitement de la rhinite allergique à l'intention de l'industrie","en":"Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry","language":["fr"],"created":"2021-06-01T19:31:50.408450","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/aerosol/publication-version-finale-ligne-directrice-exigences-relatives-innocuite-efficacite-steroides-pulverisation-nasale-commercialisation-subsequente.html","last_modified":null,"position":1,"revision_id":"98ea089c-99f2-4e64-aa38-f308351d49d2","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2011-09-19 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"56795185-65af-4c0e-b7d8-6c95442d4d1c","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This guidance is intended to assist sponsors in the collection and analysis of data for Steroid Nasal products for use in the treatment of allergic rhinitis, in order to meet the safety and effectiveness requirements under Part C, Division 8 of the Food and Drug Regulations. ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry","revision_id":"98ea089c-99f2-4e64-aa38-f308351d49d2"}